london pharma website re artimist, page-6

The sp has been punished due to the left field sort of stuff that and managements ability to deal with them.

These issues have had a huge impact on the trials, i mean at one stage they went for 3 or 4 months without hearing from PP, and the market has shown what they think of them by slashing the MC to under $10m. I doubt there is any other company in the world that is currently conducting PhIII trials on a product such as ArTmist that has a MC of less than 10m.

We now all hope that mgt have got their act together and they can get all the outstanding issues sorted by the time phIII is completed.

One can only hope.